First Hawaiian Bank Sells 5,009 Shares of Natera, Inc. (NASDAQ:NTRA)

First Hawaiian Bank lessened its position in Natera, Inc. (NASDAQ:NTRA) by 26.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,209 shares of the medical research company’s stock after selling 5,009 shares during the period. First Hawaiian Bank’s holdings in Natera were worth $2,249,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers grew its stake in shares of Natera by 4.1% in the second quarter. Rhumbline Advisers now owns 139,030 shares of the medical research company’s stock worth $15,056,000 after purchasing an additional 5,490 shares during the last quarter. TD Asset Management Inc purchased a new stake in Natera in the 2nd quarter worth approximately $1,235,000. Victory Capital Management Inc. grew its position in shares of Natera by 234.9% in the 2nd quarter. Victory Capital Management Inc. now owns 302,728 shares of the medical research company’s stock worth $32,782,000 after buying an additional 212,322 shares during the last quarter. Quest Partners LLC grew its position in shares of Natera by 22,861.5% in the 2nd quarter. Quest Partners LLC now owns 2,985 shares of the medical research company’s stock worth $323,000 after buying an additional 2,972 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Natera during the second quarter valued at approximately $322,000. Institutional investors own 99.90% of the company’s stock.

Natera Trading Up 3.6 %

NASDAQ:NTRA opened at $176.61 on Thursday. The company has a market cap of $23.32 billion, a PE ratio of -100.35 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $157.01 and a two-hundred day simple moving average of $131.05. Natera, Inc. has a 12 month low of $59.80 and a 12 month high of $177.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Research analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,709 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $206,378.84. Following the transaction, the chief executive officer now directly owns 194,615 shares in the company, valued at approximately $23,501,707.40. This trade represents a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of Natera stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 127,932 shares of company stock worth $20,635,430 in the last quarter. Company insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several recent analyst reports. Piper Sandler lifted their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Leerink Partners raised their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein upped their target price on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley raised their target price on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $153.67.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.